(±)-Tazifylline is a potent and selective long-acting histamine H1 receptor antagonist; it effectively inhibits histamine H1 receptor-mediated contractions in isolated guinea pig ileum and exhibits high affinity for H1 receptors in radioligand binding assays; it shows significantly lower affinity for histamine H2 receptors, alpha- and beta-adrenoceptors, 5-hydroxytryptamine, and muscarinic receptor subtypes; it poorly inhibits histamine release from rat peritoneal mast cells; in vivo, it demonstrates rapid-onset and long-lasting antihistaminic effects in rats, guinea pigs, and dogs; it markedly inhibits histamine-induced bronchoconstriction in anesthetized guinea pigs and protects conscious animals from lethal doses of histamine; in conscious rats, it is more potent in reducing inflammatory responses induced by intradermal histamine than those caused by anaphylactic reactions; in conscious dogs, orally administered tazifylline provides prolonged inhibition of histamine-induced skin inflammation and attenuates H1 receptor-mediated hypotension in anesthetized animals.